Engineered immune cells take on tough blood cancers

NCT ID NCT06705530

Completed Disease control Sponsor: National Research Center for Hematology, Russia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new treatment called anti-CD19 CAR-T cell therapy for adults with B-cell blood cancers that returned or didn't respond to prior treatments. The therapy uses a patient's own immune cells, modified in a lab to target and kill cancer cells. 58 adults received the treatment after a short chemotherapy course, and researchers monitored safety and cancer response for about a month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-CD19 CAR-T cells (Hemagenleukleucel)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat B-cell blood cancers that have not responded to standard therapy.
What could go wrong: This is an early-phase study (Phase I/II) with only 58 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) NON-HODGKIN LYMPHOMA,B CELL

Contacts and locations

Locations

National Medical Research Center for Hematology

Moscow, 125167, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.